Who are the top shareholders of the Biofil Chemicals?

The top shareholders of Biofil Chemicals include Scope Finance Company Private Limited with 13.9%, Starline Equifin Private Limited at 7.51%, and individual investors holding 38.31%. There are no pledged promoter holdings or mutual fund investments, and only one Foreign Institutional Investor holds a minimal stake.

The top shareholders of Biofil Chemicals include Scope Finance Company Private Limited, which holds the highest promoter stake at 13.9%. The highest public shareholder is Starline Equifin Private Limited, with a holding of 7.51%. Additionally, individual investors collectively hold 38.31% of the company's shares. There are no pledged promoter holdings and no mutual funds currently invested in the company. Only one Foreign Institutional Investor (FII) holds a stake, but it is minimal at 0.0%.

What does Biofil Chemicals do?

Biofil Chemicals & Pharmaceuticals Ltd manufactures and trades pharmaceutical products, classified as a Micro Cap company with a market cap of Rs 86 Cr. As of March 2025, it reported net sales of 8 Cr and a net profit of 0 Cr.

Overview: <BR>Biofil Chemicals & Pharmaceuticals Ltd is engaged in the manufacturing and trading of pharmaceutical products within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated as a Private Limited Company on January 4, 1985, and later converted into a Public Limited Company on May 7, 1992. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 8 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 86 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 89.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.01 <BR>Return on Equity: 2.99% <BR>Price to Book: 4.85<BR><BR>Contact Details: <BR>Address: 11/12 Sector E Sanwer Road, Sanwer Road Industrial Area Indore Madhya Pradesh : 452015 <BR>Tel: 91-731-2426700 <BR>Email: bcplcompliance@gmail.com <BR>Website: http://www.biofilgroup.net

Who are in the management team of Biofil Chemicals?

As of March 2023, the management team of Biofil Chemicals includes Ramesh Shah (Chairman & Managing Director), Romil Shah (Non Executive Director), Ketan Shah (Whole-time Director), and several Independent Directors: Shaila Jain, Satish Beohar, Ashok Kumar Ramawat, and Gayatri Padiyar, along with Shweta Verma as Company Secretary & Compliance Officer.

As of March 2023, the management team of Biofil Chemicals includes the following individuals:<BR><BR>1. Ramesh Shah - Chairman & Managing Director<BR>2. Romil Shah - Non Executive Director<BR>3. Shaila Jain - Independent Director<BR>4. Satish Beohar - Independent Director<BR>5. Ashok Kumar Ramawat - Independent Director<BR>6. Ketan Shah - Whole-time Director<BR>7. Shweta Verma - Company Secretary & Compliance Officer<BR>8. Gayatri Padiyar - Independent Director<BR><BR>Each member plays a distinct role within the organization, contributing to its governance and operational oversight.

Has Biofil Chemicals declared dividend?

No Dividend History Available

Who are the peers of the Biofil Chemicals?

Biofil Chemicals' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Rajnish Wellness, Achyut Healthcar, Lasa Supergeneri, and Sunil Healthcare. In terms of management risk, growth, and capital structure, Biofil Chemicals is rated average, with a 1-year return of -22.04%.

Peers: The peers of Biofil Chemicals are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Rajnish Wellness, Achyut Healthcar, Lasa Supergeneri, and Sunil Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Rajnish Wellness and Biofil Chemicals. Below Average management risk is noted at Achyut Healthcar, Lasa Supergeneri, and Sunil Healthcare. For growth, Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted at Biofil Chemicals, Divi's Lab., Torrent Pharma, Achyut Healthcar, Lasa Supergeneri, and Sunil Healthcare. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, Good for Torrent Pharma and Biofil Chemicals, Average for Lasa Supergeneri, and Below Average for Rajnish Wellness, Achyut Healthcar, Sunil Healthcare, and Godavari Drugs.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Rajnish Wellness has the lowest at -83.83%. Biofil Chemicals' 1-year return is -22.04%, which is significantly lower than the highest and higher than the lowest. Additionally, peers such as Rajnish Wellness, Achyut Healthcar, Lasa Supergeneri, and Sunil Healthcare have negative six-month returns.

Is Biofil Chemicals overvalued or undervalued?

As of November 11, 2024, Biofil Chemicals is considered overvalued with a PE ratio of 87.13 and an EV to EBIT ratio of 87.37, underperforming the market with a year-to-date return of -6.93% and a low ROE of 2.99%.

As of 11 November 2024, Biofil Chemicals has moved from a valuation grade of very expensive to expensive. The company is currently considered overvalued, with a PE ratio of 87.13, an EV to EBIT ratio of 87.37, and a Price to Book Value of 4.74. These ratios indicate a significant premium compared to its peers, such as Sun Pharma with a PE of 35.25 and Divi's Lab at 79.33, both of which are also in the expensive to very expensive range.<BR><BR>In comparison to the broader market, Biofil Chemicals has underperformed on a year-to-date basis, with a return of -6.93% against the Sensex's 5.66%. This trend, combined with its high valuation ratios and low ROE of 2.99%, suggests that the stock may not justify its current price level, reinforcing the conclusion that it is overvalued.

What is the technical trend for Biofil Chemicals?

As of May 5, 2025, Biofil Chemicals shows a mildly bearish trend overall, with mixed signals from various indicators, including a mildly bullish weekly MACD and bearish monthly MACD, alongside daily moving averages that are also mildly bearish.

As of 5 May 2025, the technical trend for Biofil Chemicals has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish, suggesting mixed signals across time frames. The Bollinger Bands show a bullish trend on the weekly chart but are mildly bearish on the monthly, further indicating a lack of strong momentum. Moving averages on the daily chart are mildly bearish, which aligns with the overall trend. The KST and Dow Theory both present a mildly bullish outlook on the weekly, but remain mildly bearish on the monthly. Overall, the current technical stance is mildly bearish, with key indicators such as the daily moving averages and monthly MACD contributing to this view.

How big is Biofil Chemicals?

As of 24th July, Biofil Chemicals & Pharmaceuticals Ltd has a market capitalization of 76.00 Cr, with recent net sales of 33.40 Cr and a net profit of 0.55 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Biofil Chemicals & Pharmaceuticals Ltd has a market capitalization of 76.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 33.40 Cr, while the sum of Net Profit for the same period is 0.55 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 18.20 Cr and Total Assets valued at 47.08 Cr.

When is the next results date for Biofil Chemicals?

The next results date for Biofil Chemicals is 12 August 2025.

The next results date for Biofil Chemicals is scheduled for 12 August 2025.

Are Biofil Chemicals latest results good or bad?

Biofil Chemicals' latest results are mixed; while they reported a significant increase in Profit After Tax (PAT) and Earnings per Share (EPS), there was a concerning decline in net sales and operating profit, raising questions about the company's overall financial health.

Biofil Chemicals & Pharmaceuticals has shown a mixed performance in its latest financial results for the quarter ending June 2025. On the positive side, the company reported a Profit After Tax (PAT) of Rs 2.41 crore, which is a substantial increase of 1652.7% compared to the average PAT of Rs 0.14 crore over the previous four quarters. This marks the highest PAT recorded in the last five quarters, indicating a strong improvement in profitability.<BR><BR>Additionally, the Earnings per Share (EPS) reached Rs 1.48, reflecting enhanced earnings for shareholders. The standalone net profit also saw a significant quarter-on-quarter growth of 1,105%, which is encouraging.<BR><BR>However, there are notable concerns as well. The company experienced a decline in net sales, which stood at Rs 14.78 crore for the latest six months, representing a decrease of 37.48% year-on-year. The operating profit was at its lowest in the past five quarters, and the profit before tax (PBT) was negative, raising questions about the sustainability of the business model. The reliance on non-operating income for profitability is also a red flag.<BR><BR>In summary, while Biofil Chemicals has achieved impressive growth in PAT and EPS, the decline in sales and operating profit suggests that the overall financial health of the company is under pressure. Therefore, the results can be seen as a mix of good and bad, with significant improvements in some areas but serious concerns in others.

How has been the historical performance of Biofil Chemicals?

Biofil Chemicals has experienced fluctuating financial performance, with net sales declining from 40.04 Cr in March 2024 to 33.40 Cr in March 2025, alongside decreased profitability and negative cash flow in the latest fiscal year. Total assets and liabilities increased, indicating a challenging financial environment.

Answer:<BR>The historical performance of Biofil Chemicals shows fluctuations in net sales and profitability over the years, with a notable decline in recent periods.<BR><BR>Breakdown:<BR>Biofil Chemicals reported net sales of 33.40 Cr in March 2025, down from 40.04 Cr in March 2024, but an increase from 30.04 Cr in March 2023. The total operating income followed a similar trend, peaking at 40.04 Cr in March 2024 and showing a decrease to 33.40 Cr in March 2025. The company's total expenditure, excluding depreciation, was 32.55 Cr in March 2025, down from 39.22 Cr in March 2024. Operating profit (PBDIT) for March 2025 was 1.16 Cr, slightly lower than 1.31 Cr in March 2024. Profit before tax decreased to 0.74 Cr in March 2025 from 0.87 Cr in March 2024, while profit after tax was 0.56 Cr in March 2025, compared to 0.71 Cr in March 2024. The company's total assets increased to 50.96 Cr in March 2025 from 47.08 Cr in March 2024, with total liabilities also rising to 50.96 Cr from 47.08 Cr. The cash flow from operating activities turned negative at -1.00 Cr in March 2025, contrasting with a positive cash flow of 2.00 Cr in March 2024. Overall, the data indicates a challenging financial environment for Biofil Chemicals, with declining sales and profitability in the latest fiscal year.

Should I buy, sell or hold Biofil Chemicals?

Which are the latest news on Biofil Chemicals?

Why is Biofil Chemicals falling/rising?

As of 03-Dec, Biofil Chemicals & Pharmaceuticals Ltd's stock price is Rs. 33.50, down 7.0%, and has significantly underperformed the Sensex across various time frames, including a year-to-date decline of 41.23%. Despite increased investor participation, the stock remains in a downward trend, trading below all key moving averages.

As of 03-Dec, Biofil Chemicals & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs. 33.50, which reflects a change of -2.52 (-7.0%). The stock has been underperforming significantly, with a 1-week decline of -9.78% compared to a minor drop of -0.59% in the Sensex. Over the past month, the stock has fallen by -17.67%, while the Sensex has gained +1.34%. Year-to-date, the stock is down -41.23%, contrasting sharply with the Sensex's +8.92% increase.<BR><BR>Today, the stock hit a new 52-week low of Rs. 32.6, marking a decrease of -9.49% at its intraday low. It has been on a consecutive downward trend for the last two days, with a total decline of -10.81% during this period. The stock's performance today has underperformed its sector by -6.99%. Additionally, it has shown high volatility, with an intraday volatility of 7.91%, and is trading below all key moving averages (5-day, 20-day, 50-day, 100-day, and 200-day).<BR><BR>Despite the negative trends, there has been a notable increase in investor participation, with delivery volume rising by 178.37% against the 5-day average. However, the overall liquidity remains adequate for trading. The combination of these factors indicates that the stock is currently in a downward trajectory, primarily driven by significant losses over various time frames and recent performance metrics.